Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Submitted by amarin on Tue, 03/01/2022 - 11:00
Home
Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA® European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparations for VAZKEPA Underway in Multiple Markets Plans for Regulatory Filings for Approval of VASCEPA in Several

JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level

Submitted by amarin on Thu, 02/24/2022 - 12:32
Home
Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projection BRIDGEWATER, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- JAMA Network Open has

Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022

Submitted by amarin on Tue, 02/15/2022 - 13:01
Home
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday,
Subscribe to